These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25315856)

  • 1. Towards stage specific treatments: effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia.
    Rapado-Castro M; Berk M; Venugopal K; Bush AI; Dodd S; Dean OM
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Mar; 57():69-75. PubMed ID: 25315856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial.
    Sepehrmanesh Z; Heidary M; Akasheh N; Akbari H; Heidary M
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Mar; 82():289-296. PubMed ID: 29126981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study.
    Farokhnia M; Azarkolah A; Adinehfar F; Khodaie-Ardakani MR; Hosseini SM; Yekehtaz H; Tabrizi M; Rezaei F; Salehi B; Sadeghi SM; Moghadam M; Gharibi F; Mirshafiee O; Akhondzadeh S
    Clin Neuropharmacol; 2013; 36(6):185-92. PubMed ID: 24201233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders.
    Breier A; Liffick E; Hummer TA; Vohs JL; Yang Z; Mehdiyoun NF; Visco AC; Metzler E; Zhang Y; Francis MM
    Schizophr Res; 2018 Sep; 199():395-402. PubMed ID: 29588126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial.
    Berk M; Copolov D; Dean O; Lu K; Jeavons S; Schapkaitz I; Anderson-Hunt M; Judd F; Katz F; Katz P; Ording-Jespersen S; Little J; Conus P; Cuenod M; Do KQ; Bush AI
    Biol Psychiatry; 2008 Sep; 64(5):361-8. PubMed ID: 18436195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms.
    Rossell SL; Francis PS; Galletly C; Harris A; Siskind D; Berk M; Bozaoglu K; Dark F; Dean O; Liu D; Meyer D; Neill E; Phillipou A; Sarris J; Castle DJ
    BMC Psychiatry; 2016 Sep; 16(1):320. PubMed ID: 27629871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placebo-controlled augmentation trials of the antioxidant NAC in schizophrenia: A review.
    Chen AT; Chibnall JT; Nasrallah HA
    Ann Clin Psychiatry; 2016 Aug; 28(3):190-6. PubMed ID: 27490835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial.
    Berk M; Gama CS; Sundram S; Hustig H; Koopowitz L; D'Souza R; Malloy H; Rowland C; Monkhouse A; Monkhouse A; Bole F; Sathiyamoorthy S; Piskulic D; Dodd S
    Hum Psychopharmacol; 2009 Apr; 24(3):233-8. PubMed ID: 19330802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial.
    Berk M; Dean OM; Cotton SM; Jeavons S; Tanious M; Kohlmann K; Hewitt K; Moss K; Allwang C; Schapkaitz I; Robbins J; Cobb H; Ng F; Dodd S; Bush AI; Malhi GS
    J Clin Psychiatry; 2014 Jun; 75(6):628-36. PubMed ID: 25004186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial.
    Ritsner MS; Bawakny H; Kreinin A
    Psychiatry Clin Neurosci; 2014 Jun; 68(6):432-40. PubMed ID: 24548129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis.
    Cotton SM; Berk M; Watson A; Wood S; Allott K; Bartholomeusz CF; Bortolasci CC; Walder K; O'Donoghue B; Dean OM; Chanen A; Amminger GP; McGorry PD; Burnside A; Uren J; Ratheesh A; Dodd S
    Trials; 2019 Nov; 20(1):658. PubMed ID: 31779696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive effects of adjunctive N-acetyl cysteine in psychosis.
    Rapado-Castro M; Dodd S; Bush AI; Malhi GS; Skvarc DR; On ZX; Berk M; Dean OM
    Psychol Med; 2017 Apr; 47(5):866-876. PubMed ID: 27894373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
    Lerner V; Miodownik C; Gibel A; Sirota P; Bush I; Elliot H; Benatov R; Ritsner MS
    J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multi-centre, double-blind, 12-week, randomized, placebo-controlled trial to assess the efficacy of adjunctive N-Acetylcysteine for treatment-resistant PTSD: a study protocol.
    Maier A; Dharan A; Oliver G; Berk M; Redston S; Back SE; Kalivas P; Ng C; Kanaan RA
    BMC Psychiatry; 2020 Aug; 20(1):397. PubMed ID: 32762663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder.
    Magalhães PV; Dean OM; Bush AI; Copolov DL; Weisinger D; Malhi GS; Kohlmann K; Jeavons S; Schapkaitz I; Anderson-Hunt M; Berk M
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Apr; 37(1):132-5. PubMed ID: 22212173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Akhondzadeh S; Malek-Hosseini M; Ghoreishi A; Raznahan M; Rezazadeh SA
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1879-83. PubMed ID: 18801405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
    Akhondzadeh S; Safarcherati A; Amini H
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
    Umbricht D; Alberati D; Martin-Facklam M; Borroni E; Youssef EA; Ostland M; Wallace TL; Knoflach F; Dorflinger E; Wettstein JG; Bausch A; Garibaldi G; Santarelli L
    JAMA Psychiatry; 2014 Jun; 71(6):637-46. PubMed ID: 24696094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial.
    Usall J; Huerta-Ramos E; Iniesta R; Cobo J; Araya S; Roca M; Serrano-Blanco A; Teba F; Ochoa S
    J Clin Psychiatry; 2011 Nov; 72(11):1552-7. PubMed ID: 21903021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-acetylcysteine add-on treatment leads to an improvement of fornix white matter integrity in early psychosis: a double-blind randomized placebo-controlled trial.
    Klauser P; Xin L; Fournier M; Griffa A; Cleusix M; Jenni R; Cuenod M; Gruetter R; Hagmann P; Conus P; Baumann PS; Do KQ
    Transl Psychiatry; 2018 Oct; 8(1):220. PubMed ID: 30315150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.